A PDE3A inhibitor
Related Products
Active Metabolite(s)
350753,4-dehydro Cilostazol
Labeled Version(s)
31790Cilostazol-d4
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cilostazol

Item No. 15035

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CAS Number
73963-72-1
Synonyms
  • OPC 13013
  • OPC 21
  • Pletaal
  • Pletal
Molecular Formula
C20H27N5O2
Formula Weight
369.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 12.5 mg/mlDMSO: 12.5 mg/mlDMSO:PBS (pH 7.2) (1:7): 0.13 mg/mlEthanol: 0.11 mg/ml
λmax
257 nm
SMILES
O=C(N1[H])CCC2=C1C=CC(OCCCCC3=NN=NN3C4CCCCC4)=C2
InChi Code
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChi Key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $33

    Add

    50 mg

    $106

    Add

    100 mg

    $179

    Add

    250 mg

    $203

    Add
    Product Description

    Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme).1 It is selective for PDE3A over PDE1, -2, -4, and -5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively).2 In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice.3 Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schrör, K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4 (Suppl 2), S14-S19 (2002).

    2. Koga, Y., Kihara, Y., Okada, M., et al. 2(1H)-Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Bioorg. Med. Chem. Lett. 8(12), 1471-1476 (1998).

    3. Reddy, S.S., Agarwal, H., and Barthwal, M.K. Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice. J. Mol. Cell. Cardiol. 123, 46-57 (2018).